Analytical Data
-
Gene name
EIF4A1
- Application
-
Alternative Names
EIF4A1；DDX2A；EIF4A；Eukaryotic initiation factor 4A-I
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P60842
-
Expression Region
2-406aa
-
AA Sequence
SASQDSRSRDNGPDGMEPEGVIESNWNEIVDSFDDMNLSESLLRGIYAYGFEKPSAIQQRAILPCIKGYDVIAQAQSGTGKTATFAISILQQIELDLKATQALVLAPTRELAQQIQKVVMALGDYMGASCHACIGGTNVRAEVQKLQMEAPHIIVGTPGRVFDMLNRRYLSPKYIKMFVLDEADEMLSRGFKDQIYDIFQKLNSNTQVVLLSATMPSDVLEVTKKFMRDPIRILVKKEELTLEGIRQFYINVEREEWKLDTLCDLYETLTITQAVIFINTRRKVDWLTEKMHARDFTVSAMHGDMDQKERDVIMREFRSGSSRVLITTDLLARGIDVQQVSLVINYDLPTNRENYIHRIGRGGRFGRKGVAINMVTEEDKRTLRDIETFYNTSIEEMPLNVADLI
-
Molecular Weight
53.5 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
EIF4A1, or Eukaryotic Translation Initiation Factor 4A1, is a vital protein involved in the initiation phase of eukaryotic protein synthesis. It functions as an RNA helicase, unwinding mRNA secondary structures to facilitate ribosome binding and translation. Given its critical role in gene expression, EIF4A1 is implicated in various cellular processes, including proliferation, differentiation, and stress responses. Alterations in EIF4A1 activity have been associated with several diseases, particularly cancer, where its overexpression is often linked to enhanced tumor growth and metastasis. As a result, EIF4A1 has emerged as a potential therapeutic target in cancer treatment, making its recombinant protein a valuable tool for studying its function and regulation. Researchers are utilizing recombinant EIF4A1 to explore its interactions with other translation factors, RNA, and small molecule inhibitors. This research aims to elucidate the mechanistic pathways governing protein synthesis and highlight the implications of EIF4A1 in disease. The ability to produce and study recombinant EIF4A1 in vitro can significantly advance our understanding of translational control and open new avenues for therapeutic interventions in conditions where EIF4A1 is dysregulated.
